期刊
CLINICAL TRIALS
卷 10, 期 5, 页码 696-700出版社
SAGE PUBLICATIONS LTD
DOI: 10.1177/1740774513497540
关键词
-
资金
- NCATS NIH HHS [8UL1TR000170-05] Funding Source: Medline
- NCI NIH HHS [R01 CA075971, R01CA075971] Funding Source: Medline
- NIA NIH HHS [P50 AG005134] Funding Source: Medline
- NIDDK NIH HHS [R01 DK072381, R33 DK074099, R33DK074099, K23 DK075941, K23DK075941] Funding Source: Medline
- NINDS NIH HHS [T32NS048005, T32 NS048005] Funding Source: Medline
Background Serum creatinine has been used as the diagnostic test for acute kidney injury (AKI) for decades despite having imperfect sensitivity and specificity. Novel tubular injury biomarkers may revolutionize the diagnosis of AKI; however, even if a novel tubular injury biomarker is 100% sensitive and 100% specific, it may appear inaccurate when using serum creatinine as the gold standard. Conclusions In general, the apparent diagnostic performance of a biomarker depends not only on its ability to detect injury but also on disease prevalence and the sensitivity and specificity of the imperfect gold standard. Apparent errors in diagnosis using a new biomarker may be a reflection of errors in the imperfect gold standard itself rather than poor performance of the biomarker.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据